Business & Finance

Replimune presents new analysis from the IGNYTE study of failed melanomas of RP1 and nivolumab in anti-PD1 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting




Replimune presents new analysis from the IGNYTE study of failed melanomas of RP1 and nivolumab in anti-PD1 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Leave a Reply

Your email address will not be published. Required fields are marked *